TITLE

USE OF GENETICALLY ENGINEERED BONE-MARROW STEM CELLS TO TREAT FEMORAL DEFECTS: AN EXPERIMENTAL STUDY

AUTHOR(S)
Quanjun Cui; Zengming Xiao; Xudong Li; Saleh, Khaled J.; Balian, Gary
PUB. DATE
November 2006
SOURCE
Journal of Bone & Joint Surgery, American Volume;Nov2006 Supplement 3, Vol. 88-A, p167
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Treatment of osteonecrosis continues to be a challenging problem. The replacement of necrotic bone with graft materials that promote osteogenesis and angiogenesis may provide better outcomes for early stage disease. In this study, genetically engineered bone-marrow stem cells were used to enhance repair of a defect in the distal aspect of the femur. Methods: Cloned bone-marrow stem cells were transfected with traceable genes. Osteoblastic and angiogenic properties of the cells were analyzed. A defect was created bilaterally in the distal portion of the femur of twenty-four mice to mimic a core decompression procedure. The cloned cells were transplanted into each defect of the right femur while the left femur served as control. Bone formation was evaluated radiographically and histomorphometrically. In addition, in twenty-four additional mice, the cells were injected into subcutaneous sites, muscles, and into the renal capsule (eight mice in each group) to evaluate ectopic osteogenesis. Results: Radiopaque tissue appeared two weeks after the cells were transplanted into bone defects and at ectopic sites. Histologic analysis demonstrated that these tissues consisted of newly formed bone from transplanted cells that expressed traceable genes. Four of six bone defects that received cell transplantation were filled with new bone at four weeks, and all of the defects (n = 6) demonstrated complete healing at six weeks. On the control side, complete repair was seen in only two of six bone defects at four weeks and in three of six defects at six weeks. Histomorphometric analysis showed that transplantation of marrow stem cells into bone defects produced more bone at an earlier time-point than occurred in the controls. Conclusions: This study demonstrated that cloned bone-marrow stem cells can directly form bone after transplantation into bone defects and at ectopic sites, indicating that the in vitro expanded bone-marrow stem cells can serve as a graft material to enhance bone repair and to treat osteonecrosis. Clinical Relevance: As an alternative graft material, bone-marrow stem cells may provide new and as yet technologically unachievable solutions to many clinical problems in the areas of musculoskeletal reconstruction and tissue regeneration.
ACCESSION #
22878576

 

Related Articles

  • Synovial fluid metabolites in osteonecrosis. J. R. Bowers; Z. Dailiana; J. L. Huebner; J. R. Urbaniak; V. B. Kraus // Rheumatology;Mar2007, Vol. 46 Issue 3, p523 

    Objectives. Osteonecrosis of the femoral head results from interruption of the vascular supply and eventual death of the cellular portion of bone. Effective methods of monitoring response to treatment are needed. Our aim was to evaluate synovial fluid metabolites, glucose and lactate, as...

  • The effects of autologous bone marrow mesenchymal stem cell arterial perfusion on vascular repair and angiogenesis in osteonecrosis of the femoral head in dogs. Jin, Hongting; Xia, Bingjiang; Yu, Nanze; He, Bangjian; Shen, Yan; Xiao, Luwei; Tong, Peijian // International Orthopaedics;Dec2012, Vol. 36 Issue 12, p2589 

    Purpose: The purpose of this study was to observe the effects of marrow mesenchymal stem cell (MSCs) arterial perfusion on vascular repair and angiogenesis in osteonecrosis of the femoral head (ONFH). Methods: Twelve healthy male adult Beagle dogs were randomly divided into two groups: group A...

  • VEGF signaling pathway inhibitors and hypertension: A review for oncologists. Michaud, Laura Boehnke // Hem/Onc Today;5/25/2010, Vol. 11 Issue 10, p71 

    The article evaluates the performance of vascular endothelial growth factor (VEGF) signalling pathway inhibitors in the angiogenesis process.

  • Anti-VEGF Therapy to Treat Corneal Neovascularization. Papathanassiou, M.; Theodoropoulou, S.; Analitis, S.; Tzonou, A. // Review of Ophthalmology;Jun2013, Vol. 20 Issue 6, p77 

    The article discusses the role of anti-vascular endothelial growth factor (VEGF) therapy in treatment of corneal neovascularization.

  • Anti-angiogenic role of Ankaferd on chick chorioallontoic membrane model. GÜLŞEN, Mert Ruşen; UZUNAY, Nur Sena; FERMANLI, Orhan; ÖZTÜRK, Duygu; ÇOBAN, Zehra Dilşad; GÜRAN, Şefik; HAMİDİ, Maiwand; AVCU, Ferit // Gulhane Medical Journal;eyl2015, Vol. 57 Issue 3, p274 

    Angiogenesis is needed for tumor growth and metastasis. For this reason, it represents an exciting target for cancer treatment. Some anti-angiogenic drugs may be useful to prevent angiogenesis during cancer treatment. The aim of this study is to investigate if Ankaferd (standardized herbal...

  • The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy. POżAROWSKA, DOROTA; POŻAROWSKI, PIOTR // Central European Journal of Immunology;2016, Vol. 41 Issue 3, p311 

    Angiogenesis is a clue process for tissue development and function, both in normal and pathological conditions. This process is regulated by multiple molecular systems. One of the most potent is vascular endothelial growth factor (VEGF) and its receptor (VEGFR) system. Members of this family are...

  • Abnormal Vascular Endothelial Growth Factor Expression in Mesenchymal Stem Cells from both Osteonecrotic and Osteoarthritic Hips. Mwale, Fackson; Hongtian Wang; Johnson, Aaron J.; Mont, Michael A.; Antoniou, John // Bulletin of the NYU Hospital for Joint Diseases;2011, Vol. 69 Issue S1, pS56 

    In osteonecrosis (ON) of the hip, interruption of angiogenesis is a pathological process that may lead to impairment of the nutrient supply, cell death, and the collapse of bone. However, the process of angiogenesis in ON is not well understood. The purpose of this study was to investigate the...

  • Treatment of femoral head osteonecrosis with advanced cell therapy in sheep. Vélez, Roberto; Hernández-Fernández, Alberto; Caminal, Marta; Vives, Joaquim; Soldado, Francisco; Fernández, Alejandro; Pla, Arnau; Aguirre, Marius // Archives of Orthopaedic & Trauma Surgery;Nov2012, Vol. 132 Issue 11, p1611 

    Background: The purpose of this study was to evaluate the efficacy of core decompression associated with advanced cell therapy for the treatment of femoral head osteonecrosis in an established sheep model. Methods: Early stage osteonecrosis of the right hip was induced cryogenically in 15 mature...

  • Angiogenic switch during tumor progression of carcinoma ex-pleomorphic adenoma. A. Soares; P. Juliano; V. Araujo; K. Metze // Virchows Archiv;Jul2007, Vol. 451 Issue 1, p65 

    Abstract  We analyzed the tumor vascularization in carcinomas ex-pleomorphic adenoma (CXPA) to investigate the angiogenic switch during the malignant transformation of pleomorphic adenoma (PA) to carcinoma and during tumor progression. In eight cases of early CXPA (intracapsular and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics